Nov 08, 2022 / 04:35PM GMT
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst
All right. Perfect. Welcome, everyone, to the Credit Suisse Annual Healthcare Conference. I'm Tiago Fauth, I'm a lead biotech analyst at CS. We're joined today by BioMarin. We have Jeff, Chief Commercial Officer; and Brian, Chief Financial Officer for a fireside chat today. We'll try to leave about 5 minutes towards the end for Q&A if there are any questions from the audience.
Questions and Answers:
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research AnalystBut I guess to kick it off, let's start big picture as BioMarin is kind of evolving towards larger indications in VOXZOGO ultra-rare. What does that mean in terms of the business strategy, operating leverage investments in the early stage pipeline, and we'll get into some more specifics following that.
Brian R. Mueller - BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO
Yes, great. Thanks so